文献速递心脑血管急症重症综合管理与镇静镇痛

经皮硝酸甘油在急性卒中中的获益与安全性:随机试验的系统评价与Meta分析

Benefits and safety of transdermal glyceryl trinitrate in acute stroke: A systematic review and meta-analysis of randomized trials.
PubMed 文献 · Acad Emerg Med · 2021-12-04
一句话结论经皮硝酸甘油可降低急性卒中患者血压,但不改善90天死亡或功能结局,即使超早期(≤6小时)亦无临床获益,且增加头痛和低血压风险。

该系统评价与Meta分析纳入7项随机试验共5363例急性卒中患者,比较经皮硝酸甘油与安慰剂/对照。经皮硝酸甘油降低治疗后24小时收缩压(MD=-4.74 mmHg,95%CI -6.03至-3.45)和舒张压(MD=-2.94 mmHg,95%CI -3.74至-2.13),但未影响4-10天死亡率(RR=1.11,95%CI 0.82-1.49)、90天死亡率(RR=0.96,95%CI 0.77-1.19)和90天mRS>2(RR=0.98,95%CI 0.93-1.03)。主要结局证据质量高,未检测到亚组效应,试验序贯分析一般支持主要结局结论。经皮硝酸甘油不改变临床结局,即使超早期(≤6小时)亦无获益,且增加头痛和低血压风险。

要点

  • 急性卒中(含脑出血)经皮硝酸甘油降低24小时收缩压(MD=-4.74 mmHg,95%CI -6.03至-3.45)和舒张压(MD=-2.94 mmHg,95%CI -3.74至-2.13)。
  • 经皮硝酸甘油未改善90天功能结局(mRS>2:RR=0.98,95%CI 0.93-1.03)或90天死亡率(RR=0.96,95%CI 0.77-1.19)。
  • 超早期(≤6小时)亚组亦未见临床获益,主要结局证据质量高,未检测到亚组效应。
  • 经皮硝酸甘油增加头痛和低血压风险,用药期间需监测血压和头痛。
  • 试验序贯分析一般支持主要结局结论,不改变无效的判断。

适用人群与场景

  • 急性卒中患者,包括脑出血和缺血性卒中,涵盖超早期(≤6小时)和>6小时、院前和非院前、接受和未接受溶栓的缺血性卒中患者。

红旗征与不能漏的情况

  • 经皮硝酸甘油增加头痛和低血压风险,需监测血压和头痛。

研究设计与关键结果

  • 7项随机试验共5363例急性卒中患者,比较经皮硝酸甘油与安慰剂/对照。
  • 经皮硝酸甘油降低治疗后24小时收缩压(MD=-4.74 mmHg,95%CI -6.03至-3.45)和舒张压(MD=-2.94 mmHg,95%CI -3.74至-2.13)。
  • 经皮硝酸甘油未影响4-10天死亡率(RR=1.11,95%CI 0.82-1.49)、90天死亡率(RR=0.96,95%CI 0.77-1.19)和90天mRS>2(RR=0.98,95%CI 0.93-1.03)。
  • 主要结局证据质量高,未检测到亚组效应(脑出血 vs 缺血性卒中、轻型NIHSS≤5 vs 重型NIHSS>5缺血性卒中、缺血性卒中溶栓 vs 未溶栓、院前 vs 非院前、随机化时间≤6小时 vs >6小时、高 vs 低总体偏倚风险)。
  • 经皮硝酸甘油未影响次要结局,但增加头痛和低血压风险。
  • 试验序贯分析一般支持主要结局结论。

证据类型、等级与局限

  • 系统评价与Meta分析,纳入7项随机试验,共5363例患者。
  • 使用改良Cochrane偏倚风险评估工具评估偏倚风险,采用GRADE评估证据质量。
  • 主要结局证据质量高。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 经皮硝酸甘油可降低急性卒中患者血压,但不改善临床结局,即使超早期(≤6小时)亦无获益。
  • 使用经皮硝酸甘油时需监测头痛和低血压。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Transdermal glyceryl trinitrate (GTN) has potential beneficial properties in acute stroke including intracerebral hemorrhage (ICH) and possible clinical benefits suggested in ultra-early stroke (≤6 h). Our meta-analysis updated the evidence on its safety and benefits in acute stroke.

METHODS: We searched major electronic databases for randomized trials comparing transdermal GTN versus placebo/control in acute stroke. Primary outcomes were mortality, 90-day modified Rankin Scale (mRS), and blood pressure (BP) effects. Secondary outcomes included early, late, resource utilization, and surrogate outcomes. Safety outcomes were adverse events. Reviewers identified studies, extracted data, and assessed risk of bias (RoB) using a modified Cochrane RoB instrument and quality of evidence (QoE) using GRADE. We also performed a priori subgroup and trial sequential analyses (TSA) on primary outcomes. These subgroup analyses were ICH versus ischemic stroke, minor (NIHSS ≤5) versus major (NIHSS >5) ischemic stroke, ischemic stroke with versus without thrombolysis, prehospital versus non prehospital settings, time from stroke to randomization ≤6 h versus >6 h, and high versus low overall RoB studies.

RESULTS: Seven eligible primary trials enrolled 5363 patients. GTN reduced BP (mean difference [MD] = -4.74 mm Hg, 95% confidence interval [CI] = -6.03 to -3.45 mm Hg] and diastolic BP (MD = -2.94 mm Hg, 95% CI = -3.74 to -2.13 mm Hg) 24 h posttreatment but did not affect 4- to 10-day mortality (relative risk [RR] = 1.11, 95% CI = 0.82 to 1.49), 90-day mortality (RR = 0.96, 95% CI = 0.77 to 1.19), and 90-day mRS >2 (RR = 0.98, 95% CI = 0.93 to 1.03) compared to control/placebo. The QoE was high for primary outcomes with no subgroup effects detected. GTN did not affect secondary outcomes and increased risk of headache and hypotension. TSA generally supported our conclusions regarding primary outcomes.

CONCLUSIONS: Transdermal GTN reduces BP in acute stroke but does not alter clinical outcomes even in ultra-early stroke (≤6 h).

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Lim BL, Lee WF, Ng WM, et al. Benefits and safety of transdermal glyceryl trinitrate in acute stroke: A systematic review and meta-analysis of randomized trials. Acad Emerg Med. 2021. PMID: 34741770. doi:10.1111/acem.14408

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。